Pharma Mar (CHIX:PHME) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:PHME Pharma Mar SA CHIX:PHME
77 GF Score
Price €66.30
GF Value €71.34
! 2 Warning Signs
View Full Analysis

What is Pharma Mar Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharma Mar  (CHIX:PHMe) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Pharma Mar Cyclically Adjusted PS Ratio Related Terms


Pharma Mar Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Pharma Mar's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar Cyclically Adjusted PS Ratio Chart

Pharma Mar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.82 6.41 3.04 6.22 6.51

Pharma Mar Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.25 7.80 6.51 7.44 5.63

CHIX:PHME vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Pharma Mar's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Cyclically Adjusted PS Ratio falls into.


CHIX:PHME
77GF Score
Pharma Mar SA CHIX:PHME
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Mar Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Pharma Mar's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Pharma Mar's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.861/131.3300*131.3300
=2.861

Current CPI (Jun. 2026) = 131.3300.

Pharma Mar Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 2.698 100.333 3.532
201609 2.565 99.737 3.378
201612 2.244 101.842 2.894
201703 2.456 100.896 3.197
201706 2.773 101.848 3.576
201709 2.343 101.524 3.031
201712 1.899 102.975 2.422
201803 1.509 102.122 1.941
201806 2.092 104.165 2.638
201809 1.213 103.818 1.534
201812 1.084 104.193 1.366
201903 1.054 103.488 1.338
201906 1.192 104.612 1.496
201909 1.143 103.905 1.445
201912 1.262 105.015 1.578
202003 5.377 103.469 6.825
202006 3.766 104.254 4.744
202009 2.868 103.521 3.638
202012 2.639 104.456 3.318
202103 2.830 104.857 3.544
202106 2.619 107.102 3.211
202109 2.499 107.669 3.048
202112 4.969 111.298 5.863
202203 2.937 115.153 3.350
202206 2.667 118.044 2.967
202212 3.034 117.650 3.387
202303 1.877 118.948 2.072
202306 2.571 120.278 2.807
202309 2.083 121.343 2.254
202312 2.296 121.300 2.486
202403 2.152 122.762 2.302
202406 2.430 124.409 2.565
202409 2.588 123.121 2.761
202412 2.752 124.753 2.897
202503 2.211 125.531 2.313
202506 3.209 127.251 3.312
202509 2.046 126.840 2.118
202512 5.182 128.400 5.300
202603 2.471 129.860 2.499
202606 2.861 131.330 2.861

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Pharma Mar (CHIX:PHME) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued. The current stock price of €66.30 is trading 7.1% below its estimated GF Value™ of €71.34.

Key valuation signals for CHIX:PHME:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €71.34 vs. price of €66.30 (7.1% below fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the CHIX:PHME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharma Mar Business Description

Address Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
77GF Score

Get the complete analysis for CHIX:PHME

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€66.30
Price
€71.34
GF Value